plus extended-release dipyridamole (200 mg) given twice daily, or clopidogrel (75 mg) given once daily. The study was sponsored by the maker of the aspirin/dipyridamole combination (Aggrenox).

For prolonged antithrombotic treatment after percutaneous coronary intervention (PCI), clopidogrel monotherapy was more effective and at least as safe as aspirin monotherapy in a high-risk population, ...